Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (528) clinical trials

Do you or someone you know have worsening memory or mild cognitive impairment? Then you may be interested in the EXPEDITION-PRO clinical research study. We're looking for volunteers to help us find out whether an investigational medication can slow the rate of cognitive and functional decline. To learn more please ...

Phase N/A

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

Phase

The purpose of this study is to evaluate Donepezil and Memantine for the treatment of Alzheimer's disease.

Phase

This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Phase

SPRI is currently participating in a multi-center, 24-month clinical evaluation of an investigational drug for people suffering from mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD).

Phase N/A

SPRI Clinical Trials of Brooklyn, under the sponsorship of Suven Life Sciences, is currently participating in the clinical evaluation of the safety and effectiveness of an investigational drug in persons with moderate dementia due to Alzheimer’s disease.

Phase

A Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Aducanumab in subject’s with Early Alzheimer’s Disease.

Phase N/A

Researchers are studying a drug called BAN2401 in people who have early Alzheimer's disease . People with Alzheimer's disease have a buildup of abnormal protein, known as amyloid, in their brains. BAN2401 may reduce the amount of this abnormal protein. The study drug will be given through injection into a ...

Phase

Primary objective: to evaluate the efficacy of AZD3293 on cognitive and functional outcomes in patients with early Alzheimer’s disease (AD) as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score. Early AD is defined as the continuum of patients with mild cognitive impairment (MCI) due to AD ...

Phase N/A

Eli Lilly and Company (Lilly) is developing LY3202626, a synthetic small molecule which is a potent inhibitor of β-site amyloid precursor protein (APP)-cleaving enzyme [BACE]1, for the treatment of Alzheimer’s disease (AD). It is hypothesized that inhibition of BACE1 may slow or inhibit the progression of AD. Study I7X-MC-LLCF (LLCF), ...

Phase